MTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Chen, Weina ^a   Drakos, Elias ^a   Grammatikakis, Ioannis ^a   Schlette, Ellen J ^a   Li, Jiang ^a   Leventaki, Vasiliki ^a   Staikou Drakopoulou, Efi ^b   Patsouris, Efstratios ^b   Panayiotidis, Panayiotis ^c   Medeiros, L Jeffrey ^a   Rassidakis, George Z ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; INITIATION FACTOR 4E BINDING PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; RIBSOSOMAL PROTEIN S6 KINASE; S6 KINASE; UNCLASSIFIED DRUG; CD135 ANTIGEN; EIF4EBP1 PROTEIN, HUMAN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CELL SURVIVAL; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; APOPTOSIS; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

MAMMALIA; RAPTORES;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; PHOSPHOPROTEINS; RIBOSOMAL PROTEIN S6; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 78149237281     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-292     Document Type: Article

References (20)

1. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002, 21:3314-3333. 10.1038/sj.onc.1205317, 12032772.
2. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J, Buerger H, Muller-Tidow C, Choudhary C, McMahon M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005, 65:9643-9650. 10.1158/0008-5472.CAN-05-0422, 16266983.
3. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman J, Porwit A, Thiele J, Bloomfield CD. Acute myeloid leukemia with recurent genetic abnormalities. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 110-123. Lyon, France: IARC Press, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, 4, World Health Organization Classification of Tumours.
4. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22. 10.1016/j.ccr.2007.05.008, 17613433.
5. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10:307-318. 10.1038/nrm2672, 19339977.
6. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101. 10.1126/science.1106148, 15718470.
7. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534. 10.1182/blood-2004-06-2494, 15550488.
8. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004, 101:3130-3135. 10.1073/pnas.0400063101, 365755, 14976243.
9. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD. PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol 2008, 140:344-347. 10.1111/j.1365-2141.2007.06920.x, 18053070.
10. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007, 109:3509-3512. 10.1182/blood-2006-06-030833, 1852241, 17179228.
11. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008, 111:379-382. 10.1182/blood-2007-03-080796, 17878402.
12. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009, 2:pe24. 10.1126/scisignal.267pe24, 19383975.
13. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994, 269:5241-5248.
14. Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A. FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood 2006, 107:2094-2097. 10.1182/blood-2005-08-3317, 16304046.
15. Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 2008, 111:3723-3734. 10.1182/blood-2007-09-114454, 2275029, 18184863.
16. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S, Corbacioglu A, Lottaz C, Krauter J, Frohling S, et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007, 110:1291-1300. 10.1182/blood-2006-10-049783, 17485551.
17. Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW, Hiddemann W, Spiekermann K. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood 2005, 105:3679-3685. 10.1182/blood-2004-06-2459, 15626738.
18. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003, 17:120-124. 10.1038/sj.leu.2402740, 12529668.
19. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006, 66:6589-6597. 10.1158/0008-5472.CAN-05-3018, 16818631.
20. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006, 169:2171-2180. 10.2353/ajpath.2006.051078, 1762462, 17148679.